NEW YORK (GenomeWeb News) – GlaxoSmithKline will use Cellzome's chemical proteomics platform to identify potential candidates for small-molecule drugs for immunoinflammatory disease.
Under terms of the agreement, GSK will have exclusive access to Cellzome's Episphere technology for epigenetic research on immunoinflammatory disease. As part of the deal, Cellzome will receive from the drug maker a €33 million ($45 million) up-front payment. If the programs under this alliance are successfully developed and commercialized, Cellzome could be eligible for milestone payments of over €475 million.
The firms will work together using the Episphere technology to identify candidates against targets from four different epigenetic target classes. The partners will share responsibility for the programs until candidates are identified, when GSK will take over preclinical and clinical development and commercialization.
The Episphere technology enables researchers to screen and profile inhibitors of epigenetic targets in their native environments, including lysate cells and tissues, said Cellzome.